Protein Summary
Acts with TAL1/SCL to regulate red blood cell development. Also acts with LDB1 to maintain erythroid precursors in an immature state. LMO2 encodes a cysteine-rich, two LIM-domain protein that is required for yolk sac erythropoiesis. The LMO2 protein has a central and crucial role in hematopoietic development and is highly conserved. The LMO2 transcription start site is located approximately 25 kb downstream from the 11p13 T-cell translocation cluster (11p13 ttc), where a number T-cell acute lymphoblastic leukemia-specific translocations occur. Alternative splicing results in multiple transcript variants encoding different isoforms.[provided by RefSeq, Nov 2008]
- ENST00000257818
- ENSP00000257818
- ENSG00000135363
- ENST00000395833
- ENSP00000379175
- ENST00000411482
- ENSP00000401967
- RBTN2
- RBTNL1
- RHOM2
- TTG2
- TTG2
- LMO-2
- RBTN2
- RHOM2
- RBTNL1
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
PubMedID | 0.99 | ||
virus perturbation | 0.99 | ||
molecular function | 0.98 | ||
kinase perturbation | 0.96 | ||
disease perturbation | 0.93 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 300.53 (req: < 5)
Gene RIFs: 90 (req: <= 3)
Antibodies: 682 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 300.53 (req: >= 5)
Gene RIFs: 90 (req: > 3)
Antibodies: 682 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 13
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0